Cell Therapy Manufacturing Market 2018-2030

Abstract

The project “Cell Therapy Manufacturing Market, 2018-2030” provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. Cell therapy is based on the premise that the patient’s own cells (autologous) or those from a healthy donor (allogeneic) can be programmed to combat certain types of diseases when they are re-infused into the body. These therapies are anticipated to emerge as viable alternatives to conventional treatment options. The scope of this project primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies.